<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Oncologist</journal-id><journal-id journal-id-type="iso-abbrev">Oncologist</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)1549-490X</journal-id><journal-id journal-id-type="publisher-id">The Oncologist</journal-id><journal-id journal-id-type="pmc">oncologist</journal-id><journal-id journal-id-type="hwp">theoncologist</journal-id><journal-title-group><journal-title>The Oncologist</journal-title></journal-title-group><issn pub-type="ppub">1083-7159</issn><issn pub-type="epub">1549-490X</issn><publisher><publisher-name>AlphaMed Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29472310</article-id><article-id pub-id-type="pmc">5947454</article-id><article-id pub-id-type="doi">10.1634/theoncologist.2017-0689</article-id><article-id pub-id-type="publisher-id">ONCO12378</article-id><article-categories><subj-group subj-group-type="hwp-journal-coll"><subject>4</subject><subject>11</subject><subject>31</subject></subj-group><subj-group subj-group-type="heading"><subject>Clinical Trial Results</subject></subj-group></article-categories><title-group><article-title>Temozolomide Plus Bevacizumab in Elderly Patients with Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial (ATAG)</article-title></title-group><contrib-group><contrib id="onco12378-cr-0001" contrib-type="author"><name><surname>Reyes&#x02010;Botero</surname><given-names>Germ&#x000e1;n</given-names></name><address><email>germanreyes77@hotmail.com</email></address><xref ref-type="correspondence-address" rid="correspondenceTo">*</xref><xref ref-type="aff" rid="onco12378-aff-0001"><sup>a</sup></xref></contrib><contrib id="onco12378-cr-0002" contrib-type="author"><name><surname>Cartalat&#x02010;Carel</surname><given-names>St&#x000e9;phanie</given-names></name><xref ref-type="aff" rid="onco12378-aff-0002"><sup>b</sup></xref><xref ref-type="aff" rid="onco12378-aff-0003"><sup>c</sup></xref></contrib><contrib id="onco12378-cr-0003" contrib-type="author"><name><surname>Chinot</surname><given-names>Olivier L.</given-names></name><xref ref-type="aff" rid="onco12378-aff-0004"><sup>d</sup></xref></contrib><contrib id="onco12378-cr-0004" contrib-type="author"><name><surname>Barrie</surname><given-names>Maryline</given-names></name><xref ref-type="aff" rid="onco12378-aff-0004"><sup>d</sup></xref></contrib><contrib id="onco12378-cr-0005" contrib-type="author"><name><surname>Taillandier</surname><given-names>Luc</given-names></name><xref ref-type="aff" rid="onco12378-aff-0005"><sup>e</sup></xref></contrib><contrib id="onco12378-cr-0006" contrib-type="author"><name><surname>Beauchesne</surname><given-names>Patrick</given-names></name><xref ref-type="aff" rid="onco12378-aff-0005"><sup>e</sup></xref></contrib><contrib id="onco12378-cr-0007" contrib-type="author"><name><surname>Catry&#x02010;Thomas</surname><given-names>Isabelle</given-names></name><xref ref-type="aff" rid="onco12378-aff-0006"><sup>f</sup></xref></contrib><contrib id="onco12378-cr-0008" contrib-type="author"><name><surname>Barri&#x000e8;re</surname><given-names>J&#x000e9;r&#x000f4;me</given-names></name><xref ref-type="aff" rid="onco12378-aff-0007"><sup>g</sup></xref></contrib><contrib id="onco12378-cr-0009" contrib-type="author"><name><surname>Guillamo</surname><given-names>Jean&#x02010;Sebastien</given-names></name><xref ref-type="aff" rid="onco12378-aff-0008"><sup>h</sup></xref></contrib><contrib id="onco12378-cr-00010" contrib-type="author"><name><surname>Fabbro</surname><given-names>Michel</given-names></name><xref ref-type="aff" rid="onco12378-aff-0009"><sup>i</sup></xref></contrib><contrib id="onco12378-cr-00011" contrib-type="author"><name><surname>Frappaz</surname><given-names>Didier</given-names></name><xref ref-type="aff" rid="onco12378-aff-0010"><sup>j</sup></xref></contrib><contrib id="onco12378-cr-00012" contrib-type="author"><name><surname>Benouaich&#x02010;Amiel</surname><given-names>Alexandra</given-names></name><xref ref-type="aff" rid="onco12378-aff-0011"><sup>k</sup></xref></contrib><contrib id="onco12378-cr-00013" contrib-type="author"><name><surname>Le Rhun</surname><given-names>Emilie</given-names></name><xref ref-type="aff" rid="onco12378-aff-0012"><sup>l</sup></xref></contrib><contrib id="onco12378-cr-00014" contrib-type="author"><name><surname>Campello</surname><given-names>Chantal</given-names></name><xref ref-type="aff" rid="onco12378-aff-0013"><sup>m</sup></xref></contrib><contrib id="onco12378-cr-00015" contrib-type="author"><name><surname>Tennevet</surname><given-names>Isabelle</given-names></name><xref ref-type="aff" rid="onco12378-aff-0014"><sup>n</sup></xref></contrib><contrib id="onco12378-cr-00016" contrib-type="author"><name><surname>Ghiringhelli</surname><given-names>Fran&#x000e7;ois</given-names></name><xref ref-type="aff" rid="onco12378-aff-0015"><sup>o</sup></xref></contrib><contrib id="onco12378-cr-00017" contrib-type="author"><name><surname>Tanguy</surname><given-names>Marie&#x02010;Laure</given-names></name><xref ref-type="aff" rid="onco12378-aff-0016"><sup>p</sup></xref></contrib><contrib id="onco12378-cr-00018" contrib-type="author"><name><surname>Mokhtari</surname><given-names>Karima</given-names></name><xref ref-type="aff" rid="onco12378-aff-0016"><sup>p</sup></xref><xref ref-type="aff" rid="onco12378-aff-0017"><sup>q</sup></xref></contrib><contrib id="onco12378-cr-00019" contrib-type="author"><name><surname>Honnorat</surname><given-names>J&#x000e9;r&#x000f4;me</given-names></name><xref ref-type="aff" rid="onco12378-aff-0002"><sup>b</sup></xref><xref ref-type="aff" rid="onco12378-aff-0003"><sup>c</sup></xref></contrib><contrib id="onco12378-cr-00020" contrib-type="author"><name><surname>Delattre</surname><given-names>Jean&#x02010;Yves</given-names></name><xref ref-type="aff" rid="onco12378-aff-0001"><sup>a</sup></xref><xref ref-type="aff" rid="onco12378-aff-0017"><sup>q</sup></xref></contrib><aff id="onco12378-aff-0001"><label><sup>a</sup></label>
<institution>Service de Neurologie 2 Mazarin, Groupe Hospitalier Piti&#x000e9;&#x02010;Salp&#x000ea;tri&#x000e8;re</institution>, <city>Paris</city>, <country country="FR">France</country>
</aff><aff id="onco12378-aff-0002"><label><sup>b</sup></label>
<institution>Department of Neuro&#x02010;Oncology, Hospices Civils de Lyon, H&#x000f4;pital Neurologique</institution>, <city>Lyon</city>, <country>France</country>
</aff><aff id="onco12378-aff-0003"><label><sup>c</sup></label><institution>CNRS UMR 5310&#x02010;INSERM U1217 Institut Neuromyogene, Universit&#x000e9; Claude Bernard Lyon 1</institution>, <city>Lyon</city>, <country country="FR">France</country>
</aff><aff id="onco12378-aff-0004"><label><sup>d</sup></label><institution>Aix&#x02010;Marseille Universit&#x000e9; AP&#x02010;HMCHU Timone Service de Neuro&#x02010;Oncologie</institution>, <city>Marseille</city>, <country country="FR">France</country>
</aff><aff id="onco12378-aff-0005"><label><sup>e</sup></label><institution>CHU Nancy</institution>, <city>Nancy</city>, <country country="FR">France</country>
</aff><aff id="onco12378-aff-0006"><label><sup>f</sup></label><institution>H&#x000f4;pital Saint Andr&#x000e9; CHU</institution>, <city>Bordeaux</city>, <country country="FR">France</country>
</aff><aff id="onco12378-aff-0007"><label><sup>g</sup></label><institution>Centre Antoine Lacassagne</institution>, <city>Nice</city>, <country country="FR">France</country>
</aff><aff id="onco12378-aff-0008"><label><sup>h</sup></label><institution>CHU Caen</institution>, <city>Caen</city>, <country country="FR">France</country>
</aff><aff id="onco12378-aff-0009"><label><sup>i</sup></label><institution>Institut Regional de Cancer Montpellier</institution>, <city>Montpellier</city>, <country country="FR">France</country>
</aff><aff id="onco12378-aff-0010"><label><sup>j</sup></label><institution>Centre L&#x000e9;on B&#x000e9;rard</institution>, <city>Lyon</city>, <country country="FR">France</country>
</aff><aff id="onco12378-aff-0011"><label><sup>k</sup></label><institution>CHU Rangueil</institution>, <city>Toulouse</city>, <country country="FR">France</country>
</aff><aff id="onco12378-aff-0012"><label><sup>l</sup></label><institution>Centre Oscar Lambret</institution>, <city>Lille</city>, <country country="FR">France</country>
</aff><aff id="onco12378-aff-0013"><label><sup>m</sup></label><institution>CHU Nimes</institution>, <city>Nimes</city>, <country country="FR">France</country>
</aff><aff id="onco12378-aff-0014"><label><sup>n</sup></label><institution>Centre Henri Becquerel CLCC</institution>, <city>Rouen</city>, <country country="FR">France</country>
</aff><aff id="onco12378-aff-0015"><label><sup>o</sup></label><institution>Georges Fran&#x000e7;ois Leclerc Cancer Center</institution>, <city>Dijon</city>, <country country="FR">France</country>
</aff><aff id="onco12378-aff-0016"><label><sup>p</sup></label><institution>APHP CHU Piti&#x000e9;&#x02010;Salp&#x000ea;tri&#x000e8;re</institution>, <city>Paris</city>, <country country="FR">France</country>
</aff><aff id="onco12378-aff-0017"><label><sup>q</sup></label><institution>Universit&#x000e9; Paris VI Pierre et Marie Curie</institution>, <city>Paris</city>, <country country="FR">France</country>
</aff></contrib-group><author-notes><corresp id="correspondenceTo"><label>*</label>Correspondence: Germ&#x000e1;n Reyes&#x02010;Botero, M.D., Service de Neurologie 2 Mazarin, Groupe Hospitalier Piti&#x000e9;&#x02010;Salp&#x000ea;tri&#x000e8;re, 47&#x02010;83 Blvd de l'H&#x000f4;pital, Paris, France 75013. Telephone: 01&#x02010;42&#x02010;16&#x02010;03&#x02010;85; e&#x02010;mail: <email>germanreyes77@hotmail.com</email></corresp></author-notes><pub-date pub-type="epub"><day>22</day><month>2</month><year>2018</year></pub-date><pub-date pub-type="ppub"><month>5</month><year>2018</year></pub-date><pub-date pub-type="pmc-release"><day>22</day><month>2</month><year>2018</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>23</volume><issue>5</issue><issue-id pub-id-type="doi">10.1002/onco.v23.5</issue-id><fpage>524</fpage><lpage>e44</lpage><history><date date-type="received"><day>19</day><month>9</month><year>2017</year></date><date date-type="accepted"><day>03</day><month>12</month><year>2017</year></date></history><permissions><copyright-statement content-type="article-copyright">&#x000a9;AlphaMed Press; the data published online to support this summary is the property of the authors</copyright-statement></permissions><self-uri content-type="pdf" xlink:href="onco12378.pdf"/><abstract><title>Abstract</title><sec id="onco12378-sec-0022"><title>Lessons Learned.</title><p>
<list list-type="bullet" id="onco12378-list-0001"><list-item id="onco12378-li-0001"><p>Results suggest that the combination of bevacizumab plus temozolomide is active in terms of response rate, survival, performance, quality of life, and cognition in elderly patients with glioblastoma multiforme with poor performance status.</p></list-item><list-item id="onco12378-li-0002"><p>Whether this combination is superior to temozolomide alone remains to be demonstrated by a randomized study.</p></list-item></list></p></sec><sec id="onco12378-sec-0001"><title>Background.</title><p>The optimal treatment of glioblastoma multiforme (GBM) in patients aged &#x02265;70 years with a Karnofsky performance status (KPS) &#x0003c;70 is not established. This clinical trial evaluated the efficacy and safety of upfront temozolomide (TMZ) and bevacizumab (Bev) in patients aged &#x02265;70 years and a KPS &#x0003c;70.</p></sec><sec id="onco12378-sec-0002"><title>Materials and Methods.</title><p>Patients aged &#x02265;70 years with a KPS &#x0003c;70 and biopsy&#x02010;proven GBM were eligible for this multicenter, prospective, nonrandomized, phase II trial of older patients with impaired performance status. Treatment consisted of TMZ administered at 130&#x02013;150 mg/m<sup>2</sup> per day for 5 days every 4 weeks plus Bev administered at 10 mg/kg every 2 weeks.</p></sec><sec id="onco12378-sec-0003"><title>Results.</title><p>The trial included 66 patients (median age of 76 years; median KPS of 60). The median overall survival (OS) was 23.9 weeks (95% confidence interval [CI], 19&#x02013;27.6), and the median progression&#x02010;free survival (PFS) was 15.3 weeks (95% CI, 12.9&#x02013;19.3). Twenty&#x02010;two (33%) patients became transiently capable of self&#x02010;care (i.e., KPS &#x0003e;70). Cognition and quality of life significantly improved over time during treatment. Grade &#x02265;3 hematological adverse events occurred in 13 (20%) patients, high blood pressure in 16 (24%), venous thromboembolism in 3 (4.5%), cerebral hemorrhage in 2 (3%), and intestinal perforation in 2 (3%).</p></sec><sec id="onco12378-sec-0004"><title>Conclusion.</title><p>This study suggests that TMZ&#x02009;+&#x02009;Bev treatment is active in elderly patients with GBM with low KPS and has an acceptable tolerance level.</p></sec></abstract><trans-abstract xml:lang="zh" abstract-type="main"><p xml:lang="zh"><bold>&#x07ecf;&#x09a8c;&#x0603b;&#x07ed3;</bold></p><p xml:lang="zh"><list list-type="bullet" id="onco12378-list-1002"><list-item id="onco12378-li-1005"><p>&#x07ed3;&#x0679c;&#x08868;&#x0660e;, &#x05bf9;&#x04e8e;&#x060a3;&#x0591a;&#x05f62;&#x06027;&#x06076;&#x06027;&#x080f6;&#x08d28;&#x07624;&#x04e14;&#x04f53;&#x080fd;&#x072b6;&#x06001;&#x06b20;&#x04f73;&#x07684;&#x08001;&#x05e74;&#x060a3;&#x08005;, &#x08d1d;&#x04f10;&#x05355;&#x06297;+&#x066ff;&#x083ab;&#x05511;&#x080fa;&#x08054;&#x05408;&#x06cbb;&#x07597;&#x05728;&#x07f13;&#x089e3;&#x07387;&#x03001;&#x0751f;&#x05b58;&#x0671f;&#x03001;&#x04f53;&#x080fd;&#x03001;&#x0751f;&#x06d3b;&#x08d28;&#x091cf;&#x0548c;&#x08ba4;&#x077e5;&#x065b9;&#x09762;&#x06709;&#x06548;&#x03002;</p></list-item><list-item id="onco12378-li-1006"><p>&#x06b64;&#x08054;&#x05408;&#x06cbb;&#x07597;&#x0662f;&#x05426;&#x04f18;&#x04e8e;&#x066ff;&#x083ab;&#x05511;&#x080fa;&#x05355;&#x0836f;&#x06cbb;&#x07597;&#x06709;&#x05f85;&#x0901a;&#x08fc7;&#x0968f;&#x0673a;&#x07814;&#x07a76;&#x08bc1;&#x0660e;&#x03002;</p></list-item></list></p><p xml:lang="zh"><bold>&#x06458;&#x08981;</bold></p><p xml:lang="zh"><bold><italic>&#x080cc;&#x0666f;</italic>.</bold>&#x05c1a;&#x0672a;&#x0786e;&#x05b9a;Karnofsky&#x04f53;&#x080fd;&#x072b6;&#x06001;&#x08bc4;&#x05206;&#x0ff08;KPS&#x0ff09;&#x0003c;70&#x03001;&#x05e74;&#x09f84;&#x02265;70&#x05c81;&#x07684;&#x0591a;&#x05f62;&#x06027;&#x06076;&#x06027;&#x080f6;&#x08d28;&#x07624;&#x0ff08;GBM&#x0ff09;&#x060a3;&#x08005;&#x07684;&#x06700;&#x04f73;&#x06cbb;&#x07597;&#x03002;&#x0672c;&#x04e34;&#x05e8a;&#x08bd5;&#x09a8c;&#x08bc4;&#x04ef7;&#x04e86;&#x066ff;&#x083ab;&#x05511;&#x080fa;&#x0ff08;TMZ&#x0ff09;&#x0548c;&#x08d1d;&#x04f10;&#x05355;&#x06297;&#x0ff08;Bev&#x0ff09;&#x0521d;&#x0671f;&#x06cbb;&#x07597;&#x05728;&#x05e74;&#x09f84;&#x02265;70&#x05c81;&#x03001;KPS&#x0003c;70&#x07684;&#x060a3;&#x08005;&#x04e2d;&#x07684;&#x07597;&#x06548;&#x0548c;&#x05b89;&#x05168;&#x06027;&#x03002;</p><p xml:lang="zh"><bold><italic>&#x06750;&#x06599;&#x0548c;&#x065b9;&#x06cd5;</italic>.</bold>&#x05e74;&#x09f84;&#x02265;70&#x05c81;&#x03001;KPS&#x0003c;70&#x04e14;&#x060a3;&#x06709;&#x07ecf;&#x06d3b;&#x068c0;&#x08bc1;&#x05b9e;GBM&#x07684;&#x060a3;&#x08005;&#x06709;&#x08d44;&#x0683c;&#x053c2;&#x052a0;&#x0672c;&#x09879;&#x09488;&#x05bf9;&#x04f53;&#x080fd;&#x072b6;&#x06001;&#x053d7;&#x0635f;&#x05e74;&#x0957f;&#x060a3;&#x08005;&#x07684;&#x0591a;&#x04e2d;&#x05fc3;&#x03001;&#x0524d;&#x077bb;&#x06027;&#x03001;&#x0975e;&#x0968f;&#x0673a;&#x03001;II&#x0671f;&#x08bd5;&#x09a8c;&#x03002;&#x06cbb;&#x07597;&#x05305;&#x062ec;&#x06bcf;4&#x05468;&#x04e00;&#x06b21;&#x03001;&#x04e3a;&#x0671f;5&#x05929;&#x07684;TMZ 130&#x02013;150mg/m<sup>2</sup>/&#x05929;&#x07ed9;&#x0836f;+&#x06bcf;2&#x05468;&#x04e00;&#x06b21;Bev 10mg/kg&#x07ed9;&#x0836f;&#x03002;</p><p xml:lang="zh"><bold><italic>&#x07ed3;&#x0679c;</italic>.</bold>&#x08be5;&#x08bd5;&#x09a8c;&#x05305;&#x062ec;66&#x04f8b;&#x060a3;&#x08005;&#x0ff08;&#x04e2d;&#x04f4d;&#x05e74;&#x09f84;&#x04e3a;76&#x05c81;, &#x04e2d;&#x04f4d;KPS&#x04e3a;60&#x0ff09;&#x03002;&#x04e2d;&#x04f4d;&#x0603b;&#x0751f;&#x05b58;&#x0671f;&#x0ff08;OS&#x0ff09;&#x04e3a;23.9&#x05468;[95%&#x07f6e;&#x04fe1;&#x0533a;&#x095f4;&#x0ff08;CI&#x0ff09;&#x0ff1a;19&#x02013;27.6], &#x04e2d;&#x04f4d;&#x065e0;&#x08fdb;&#x05c55;&#x0751f;&#x05b58;&#x0671f;&#x0ff08;PFS&#x0ff09;&#x04e3a;15.3&#x05468;&#x0ff08;95% CI&#x0ff1a;12.9&#x02013;19.3&#x0ff09;&#x03002;22&#x04f8b;&#x0ff08;33%&#x0ff09;&#x060a3;&#x08005;&#x06682;&#x065f6;&#x080fd;&#x0591f;&#x081ea;&#x06211;&#x062a4;&#x07406;&#x0ff08;&#x05373;KPS&#x0003e;70&#x0ff09;&#x03002;&#x06cbb;&#x07597;&#x0671f;&#x095f4;&#x08ba4;&#x077e5;&#x0548c;&#x0751f;&#x06d3b;&#x08d28;&#x091cf;&#x05f97;&#x05230;&#x0663e;&#x08457;&#x06539;&#x05584;&#x03002;13&#x04f8b;&#x0ff08;20%&#x0ff09;&#x060a3;&#x08005;&#x053d1;&#x0751f;&#x02265;3&#x07ea7;&#x08840;&#x06db2;&#x05b66;&#x04e0d;&#x0826f;&#x04e8b;&#x04ef6;, 16&#x04f8b;&#x0ff08;24%&#x0ff09;&#x060a3;&#x08005;&#x053d1;&#x0751f;&#x09ad8;&#x08840;&#x0538b;, 3&#x04f8b;&#x0ff08;4.5%&#x0ff09;&#x060a3;&#x08005;&#x053d1;&#x0751f;&#x09759;&#x08109;&#x08840;&#x06813;&#x06813;&#x0585e;, 2&#x04f8b;&#x0ff08;3%&#x0ff09;&#x060a3;&#x08005;&#x053d1;&#x0751f;&#x08111;&#x051fa;&#x08840;, 2&#x04f8b;&#x0ff08;3%&#x0ff09;&#x060a3;&#x08005;&#x053d1;&#x0751f;&#x080a0;&#x07a7f;&#x05b54;&#x03002;</p><p xml:lang="zh"><bold><italic>&#x07ed3;&#x08bba;</italic>.</bold>&#x0672c;&#x07814;&#x07a76;&#x08868;&#x0660e;TMZ+Bev&#x06cbb;&#x07597;&#x05728;KPS&#x08f83;&#x04f4e;&#x07684;GBM&#x08001;&#x05e74;&#x060a3;&#x08005;&#x04e2d;&#x06709;&#x06548;, &#x04e14;&#x08010;&#x053d7;&#x07a0b;&#x05ea6;&#x053ef;&#x063a5;&#x053d7;&#x03002;</p></trans-abstract><counts><page-count count="8"/></counts></article-meta></front><body><sec sec-type="discussion" id="onco12378-sec-0006"><title>Discussion</title><p>Our study indicates that tolerance to the Bev&#x02010;TMZ combination was acceptable in this population. Hematological toxicity greater than grade 3 was reported in 20% of patients. As expected, the most frequent adverse event observed with Bev was high blood pressure, which responded to antihypertensive treatment. Although the rate of thromboembolic events does not appear to be exceedingly high in this bedridden GBM population, the two cases of intestinal perforation can be ascribed to Bev; furthermore, Bev may have played a role in the two cases of cerebral hemorrhage.</p><p>An objective radiological response in one third of patients and the fact that one third of patients also became autonomous and capable of self&#x02010;care (i.e., KPS &#x0003e;70) is encouraging and in agreement with the observations of significant improvements in cognition and most quality&#x02010;of&#x02010;life scales during the treatment period. Additionally, the estimated OS median of 24 weeks (Figure <xref rid="onco12378-fig-0001" ref-type="fig">1</xref>) that we found appears higher that the 12 weeks OS that we found in a similar patient population treated with supportive care alone (personal data, unpublished).</p><fig fig-type="Figure" xml:lang="en" id="onco12378-fig-0001" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>Kaplan&#x02010;Meier plot: experimental arm, primary assessment, total patient population. <bold>(A)</bold>: Kaplan&#x02010;Meier estimates of overall survival. <bold>(B)</bold>: Kaplan&#x02010;Meier estimates of progression&#x02010;free survival.</p></caption><graphic id="nlm-graphic-1" specific-use="sourcefile-name" xlink:href="onco12378-fig-0001"><alt-text>image</alt-text></graphic></fig><p>There was a trend for increased PFS and OS in patients with methylated promoter O&#x02010;6&#x02010;methylguanine&#x02010;DNA methyltransferase (MGMT) status; however, in contrast to our previous study that used TMZ alone, this difference did not reach statistical significance. This may reflect a lack of power. On the other hand, it is possible that some patients without methylated MGMT promoter also could benefit from Bev because its action is not believed to be influenced by MGMT methylation status.</p></sec><sec id="onco12378-sec-0007"><title>Trial Information</title><p>
<def-list list-type="simple" id="onco12378-lp-0001"><def-item><term id="onco12378-li-0008"><bold>Disease</bold></term><def id="onco12378-li-0009"><p>Brain cancer &#x02013; primary</p></def></def-item><def-item><term id="onco12378-li-0010"><bold>Stage of Disease/Treatment</bold></term><def id="onco12378-li-0011"><p>Primary</p></def></def-item><def-item><term id="onco12378-li-0012"><bold>Prior Therapy</bold></term><def id="onco12378-li-0013"><p>None</p></def></def-item><def-item><term id="onco12378-li-0014"><bold>Type of Study &#x02010; 1</bold></term><def id="onco12378-li-0015"><p>Phase II</p></def></def-item><def-item><term id="onco12378-li-0016"><bold>Type of Study &#x02010; 2</bold></term><def id="onco12378-li-0017"><p>Single arm</p></def></def-item><def-item><term id="onco12378-li-0018"><bold>Primary Endpoint</bold></term><def id="onco12378-li-0019"><p>Overall survival</p></def></def-item><def-item><term id="onco12378-li-0020"><bold>Secondary Endpoint</bold></term><def id="onco12378-li-0021"><p>Progression&#x02010;free survival</p></def></def-item><def-item><term id="onco12378-li-0022"><bold>Secondary Endpoint</bold></term><def id="onco12378-li-0023"><p>Tolerability</p></def></def-item><def-item><term id="onco12378-li-0024"><bold>Secondary Endpoint</bold></term><def id="onco12378-li-0025"><p>Health&#x02010;related quality of life</p></def></def-item><def-item><term id="onco12378-li-0026"><bold>Secondary Endpoint</bold></term><def id="onco12378-li-0027"><p>Cognitive functioning</p></def></def-item><def-item><term id="onco12378-li-0028"><bold>Additional Details of Endpoints or Study Design</bold></term><def id="onco12378-li-0317"><p>&#x000a0;</p></def></def-item><def-item><term id="onco12378-li-1028">The primary endpoint was median OS, and the secondary endpoints were PFS, tolerance of treatment, health&#x02010;related quality of life (European Organisation for Research and Treatment of Cancer [EORTC] quality of life questionnaires: core questionnaire [QLQ&#x02010;C30], version 3.0, and brain cancer module [QLQ&#x02010;BN20]) and cognitive functioning (mini&#x02010;mental state examination [MMSE]). The sample size was based on the accuracy of the median survival estimation. Assuming a median survival of 22 weeks and a minimum follow&#x02010;up of 12 months, it was estimated that 70 patients were needed to evaluate survival with a half width of its 95% confidence interval of 14 weeks. All patients who received at least one dose of treatment were included in the analyses. OS was calculated from the date of surgery until death. PFS was defined as the time from surgery to the date of progression or death. The survival distributions were estimated by the Kaplan&#x02010;Meier method. The log&#x02010;rank test was used to compare OS and PFS according to MGMT status. Prognostic factors for survival were examined by a stepwise Cox regression model. The factors included in the model were age and KPS at inclusion (60 vs. &#x0003c;60). A second Cox regression model was performed on the patients for whom MGMT promoter methylation assessment was available, with MGMT status, age, and KPS as covariates. Changes from baseline of health&#x02010;related quality of life scores, MMSE scores, and KPS were analyzed using a mixed&#x02010;model analysis, with time as a fixed effect and the patient as a random effect. Logistic regression was used to identify predictive factors of clinical improvement defined by a KPS &#x02265;70 at two consecutive visits. All analyses were performed using SAS software version 8.2 (SAS Institute, Cary, NC). The &#x003b1; level was set at 0.05.</term><def id="onco12378-li-0029"><p>&#x000a0;</p></def></def-item><def-item><term id="onco12378-li-0030">Baseline assessments included physical and neurological examinations, assessments of KPS, health&#x02010;related quality of life questionnaires (EORTC QLQ&#x02010;C30, version 3.0, and QLQBN20), cognitive evaluations with MMSE, complete blood counts and blood chemistry tests, and contrast&#x02010;enhanced brain computed tomography or magnetic resonance imaging. Patients were assessed every 2 weeks by physical and neurological examinations, complete blood counts, and urine strip tests. The blood chemistry tests, quality of life assessments, KPS evaluations, and MMSEs were repeated every month. Neuroimaging studies were repeated every 2 months, and tumor response was assessed using the response assessment in neuro&#x02010;oncology criteria, taking into account the perpendicular diameters of the tumor in contrasted sequences and fluid&#x02010;attenuated inversion recovery. Toxicity was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 3.0. The EORTC QLQ&#x02010;C30 and QLQ&#x02010;BN20 were used to assess health&#x02010;related quality of life. The QLQ&#x02010;C30 questionnaire includes 30 questions comprising five functioning scales (physical, role, emotional, cognitive, and social), three symptom scales (fatigue, vomiting, and pain), and six single&#x02010;item scales (dyspnea, insomnia, constipation, anorexia, diarrhea, and financial difficulties). The QLQ&#x02010;BN20 questionnaire includes 20 items covering functional deficits, symptoms, toxic effects of treatment, and uncertainty about the future. Questionnaires were filled out by patients when possible or by a companion (always the same) when the patient was unable to complete the form. The MMSE was used as a measure of general cognitive status. Higher scores on this exam, which uses a 30&#x02010;point scale, indicated better cognitive function.</term><def id="onco12378-li-0031"><p>&#x000a0;</p></def></def-item><def-item><term id="onco12378-li-0032"><bold>Investigator's Analysis</bold></term><def id="onco12378-li-0033"><p>Active and should be pursued further</p></def></def-item></def-list></p></sec><sec id="onco12378-sec-0008"><title>Drug Information</title><p>
<def-list list-type="simple" id="onco12378-lp-0002"><def-item><term id="onco12378-li-0034">Drug 1</term><def id="onco12378-li-0035"><p>&#x000a0;</p></def></def-item><def-item><term id="onco12378-li-0036">Generic/Working Name</term><def id="onco12378-li-0037"><p>Temozolomide</p></def></def-item><def-item><term id="onco12378-li-0038">Drug Type</term><def id="onco12378-li-0039"><p>Small molecule</p></def></def-item><def-item><term id="onco12378-li-0040">Drug Class</term><def id="onco12378-li-0041"><p>Alkylating agent</p></def></def-item><def-item><term id="onco12378-li-0042">Dose</term><def id="onco12378-li-0043"><p>130&#x02013;150 milligrams (mg) per square meter (m<sup>2</sup>)</p></def></def-item><def-item><term id="onco12378-li-0044">Route</term><def id="onco12378-li-0045"><p>Oral (p.o.)</p></def></def-item><def-item><term id="onco12378-li-0046">Drug 2</term><def id="onco12378-li-0047"><p>&#x000a0;</p></def></def-item><def-item><term id="onco12378-li-0048">Generic/Working Name</term><def id="onco12378-li-0049"><p>Bevacizumab</p></def></def-item><def-item><term id="onco12378-li-0050">Drug Type</term><def id="onco12378-li-0051"><p>Antibody</p></def></def-item><def-item><term id="onco12378-li-0052">Drug Class</term><def id="onco12378-li-0053"><p>Angiogenesis &#x02013; VEGF</p></def></def-item><def-item><term id="onco12378-li-0054">Dose</term><def id="onco12378-li-0055"><p>10 mg milligrams (mg) per kilogram (kg)</p></def></def-item><def-item><term id="onco12378-li-0056">Route</term><def id="onco12378-li-0057"><p>IV</p></def></def-item><def-item><term id="onco12378-li-0058">Schedule of Administration</term><def id="onco12378-li-0059"><p>Every 2 weeks</p></def></def-item></def-list></p></sec><sec id="onco12378-sec-0009"><title>Patient Characteristics</title><p>
<def-list list-type="simple" id="onco12378-lp-0003"><def-item><term id="onco12378-li-0060">Number of Patients, Male</term><def id="onco12378-li-0061"><p>24</p></def></def-item><def-item><term id="onco12378-li-0062">Number of Patients, Female</term><def id="onco12378-li-0063"><p>42</p></def></def-item><def-item><term id="onco12378-li-0064">Age</term><def id="onco12378-li-0065"><p>Median (range): 76 years (70&#x02013;87 years)</p></def></def-item><def-item><term id="onco12378-li-0066">Number of Prior Systemic Therapies</term><def id="onco12378-li-0067"><p>Median: 0</p></def></def-item><def-item><term id="onco12378-li-0068">Other</term><def id="onco12378-li-0069"><p>The median postoperative Karnofsky performance status was 60 (range, 30&#x02013;60)</p></def></def-item></def-list></p></sec><sec id="onco12378-sec-0010"><title>Primary Assessment Method</title><p>
<def-list list-type="simple" id="onco12378-lp-0004"><def-item><term id="onco12378-li-0070">Title</term><def id="onco12378-li-0071"><p>Total Patient Population</p></def></def-item><def-item><term id="onco12378-li-0072">Number of Patients Screened</term><def id="onco12378-li-0073"><p>71</p></def></def-item><def-item><term id="onco12378-li-0074">Number of Patients Enrolled</term><def id="onco12378-li-0075"><p>66</p></def></def-item><def-item><term id="onco12378-li-0076">Number of Patients Evaluable for Toxicity</term><def id="onco12378-li-0077"><p>66</p></def></def-item><def-item><term id="onco12378-li-0078">Number of Patients Evaluated for Efficacy</term><def id="onco12378-li-0079"><p>66</p></def></def-item><def-item><term id="onco12378-li-0080">Response Assessment CR</term><def id="onco12378-li-0081"><p><italic>n</italic>&#x02009;=&#x02009;1</p></def></def-item><def-item><term id="onco12378-li-0082">Response Assessment PR</term><def id="onco12378-li-0083"><p><italic>n</italic>&#x02009;=&#x02009;20</p></def></def-item><def-item><term id="onco12378-li-0084">Response Assessment SD</term><def id="onco12378-li-0085"><p><italic>n</italic>&#x02009;=&#x02009;24</p></def></def-item><def-item><term id="onco12378-li-0086">Response Assessment PD</term><def id="onco12378-li-0087"><p><italic>n</italic>&#x02009;=&#x02009;15</p></def></def-item><def-item><term id="onco12378-li-0088">(Median) Duration Assessments PFS</term><def id="onco12378-li-0089"><p>15.3 weeks; CI, 12.9&#x02013;19.3</p></def></def-item><def-item><term id="onco12378-li-0090">(Median) Duration Assessments OS</term><def id="onco12378-li-0091"><p>23.9 weeks; CI, 19&#x02013;27.6</p></def></def-item><def-item><term id="onco12378-li-0092">Kaplan&#x02010;Meier Time Units</term><def id="onco12378-li-0093"><p>Weeks</p></def></def-item></def-list></p></sec><sec id="onco12378-sec-2010"><p>
<table-wrap id="nlm-table-wrap-1" xml:lang="en" orientation="portrait" position="anchor"><graphic id="nlm-graphic-5" specific-use="sourcefile-name" xlink:href="onco12378-tbl-0001"><alt-text>image</alt-text><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></graphic></table-wrap>
</p></sec><sec id="onco12378-sec-0011"><p><bold>Kaplan&#x02010;Meier Plot Legend</bold></p><p>Kaplan&#x02010;Meier estimates of overall survival (OS)</p></sec><sec id="onco12378-sec-0012"><title>Phase II Experimental Adverse Events</title><p>
<def-list list-type="simple" id="onco12378-lp-1004"><def-item><term id="onco12378-li-1070">Tolerance to treatment was acceptable, and most adverse events (AEs) were mild to moderate. AEs of grade &#x02265;3 were observed in 37 (56%) patients and are detailed in Table <xref rid="onco12378-tbl-0002" ref-type="table">2</xref>. High blood pressure was the most frequent AE and was detected in 16 (24%) patients. It was manageable with antihypertensive medication, and Bev discontinuation was not necessary in any of those cases. Hematological AEs of grade &#x02265;3 were reported in 13 (20%) patients, including neutropenia (<italic>n</italic>&#x02009;=&#x02009;2), anemia (<italic>n</italic>&#x02009;=&#x02009;1), thrombocytopenia (<italic>n</italic>&#x02009;=&#x02009;5), and lymphopenia (<italic>n</italic>&#x02009;=&#x02009;8). Fatal myelosuppression was not observed.</term><def id="onco12378-li-1071"><p>&#x000a0;</p></def></def-item></def-list></p></sec><sec id="onco12378-sec-1012"><title>Serious Adverse Events</title><p>
<table-wrap id="nlm-table-wrap-2" xml:lang="en" orientation="portrait" position="anchor"><graphic id="nlm-graphic-7" specific-use="sourcefile-name" xlink:href="onco12378-tbl-0002"><alt-text>image</alt-text><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></graphic></table-wrap>
</p></sec><sec id="onco12378-sec-0113"><p><bold>Serious Adverse Events Legend</bold></p><p>Serious adverse events included deep venous thrombosis (three cases), pulmonary embolism (two cases, including one fatal), intestinal perforation (two cases, including one fatal), and cerebral hemorrhage (two cases, including one fatal grade 5 toxicity).</p></sec><sec id="onco12378-sec-0014"><title>Assessment, Analysis, and Discussion</title><p>
<def-list list-type="simple" id="onco12378-lp-0005"><def-item><term id="onco12378-li-0094">Completion</term><def id="onco12378-li-0095"><p>Study completed</p></def></def-item><def-item><term id="onco12378-li-0096">Investigator's Assessment</term><def id="onco12378-li-0097"><p>Active and should be pursued further</p></def></def-item></def-list></p></sec><sec id="onco12378-sec-0101"><p>Elderly patients aged 65 years and older account for approximately 45% of patients with glioblastoma multiforme (GBM) [<xref rid="onco12378-bib-0001" ref-type="ref">1</xref>], and this figure is expected to rise concurrently with the aging population of most countries [<xref rid="onco12378-bib-0002" ref-type="ref">2</xref>]. Unfortunately, few trials have been performed in this setting [<xref rid="onco12378-bib-0003" ref-type="ref">3</xref>], [<xref rid="onco12378-bib-0004" ref-type="ref">4</xref>], [<xref rid="onco12378-bib-0005" ref-type="ref">5</xref>], [<xref rid="onco12378-bib-0006" ref-type="ref">6</xref>], [<xref rid="onco12378-bib-0007" ref-type="ref">7</xref>]. In elderly patients with good functional status (Karnofsky performance status [KPS] &#x0003e;70 or Eastern Cooperative Oncology Group score 0&#x02013;2), the standard treatment is now the combination of radiotherapy (RT) and temozolomide (TMZ; concomitant and adjuvant). In elderly patients with poor functional status at the time of diagnosis (KPS &#x0003c;70), there is no standard treatment. One trial suggested that accelerated 1&#x02010;week RT could be of help, but this trial mixed various populations, including younger patients and elderly patients in good clinical condition [<xref rid="onco12378-bib-0008" ref-type="ref">8</xref>]. In elderly, bedridden patients with unresectable GBM, the benefit of radiotherapy is unproven and questionable; indeed, it requires daily trips to the hospital, resulting in increased fatigue and an increased risk of acute complications, including intracranial hypertension and herniation, particularly when high doses per fraction are used. In this very difficult patient population, we previously showed that TMZ alone was associated with improvement in functional status in one third of cases and appeared to increase survival compared with supportive care alone [<xref rid="onco12378-bib-0009" ref-type="ref">9</xref>].</p><p>Bevacizumab (Bev) is an antiangiogenic monoclonal antibody targeting vascular endothelial growth factor that is commonly used in GBM. Although recent phase III studies did not show a significant effect of adding Bev to alkylating agents (TMZ or nitrosoureas) on overall survival (OS), a favorable impact of this combination on progression&#x02010;free survival was demonstrated both as a first&#x02010;line treatment and in the recurrent setting [<xref rid="onco12378-bib-0010" ref-type="ref">10</xref>], [<xref rid="onco12378-bib-0011" ref-type="ref">11</xref>], [<xref rid="onco12378-bib-0012" ref-type="ref">12</xref>], [<xref rid="onco12378-bib-0013" ref-type="ref">13</xref>], [<xref rid="onco12378-bib-0014" ref-type="ref">14</xref>], [<xref rid="onco12378-bib-0015" ref-type="ref">15</xref>], [<xref rid="onco12378-bib-0016" ref-type="ref">16</xref>].</p><p>Treatment of GBM in elderly patients with impaired functional status is challenging. In a recursive partitioning analysis, the estimated median OS in elderly patients with GBM with a KPS &#x0003c;70 without surgical resection was only 10 weeks (95% CI, 9&#x02013;13.5) [<xref rid="onco12378-bib-0017" ref-type="ref">17</xref>]. In a recent phase II trial focusing on this frail elderly population, we found that TMZ alone was helpful with a median OS of 25 weeks (95% CI, 19&#x02013;28); 25% of patients became able to provide self&#x02010;care and had significant improvements in quality of life and cognition before disease progression [<xref rid="onco12378-bib-0009" ref-type="ref">9</xref>].</p><p>In this study, we evaluated the efficacy and safety of the upfront combination of TMZ&#x02009;+&#x02009;Bev as an initial treatment for elderly patients with GBM and impaired functional status (KPS &#x0003c;70). Bev has a well&#x02010;known steroid&#x02010;sparing effect, presumably because of the blood&#x02010;brain and blood&#x02010;tumor barrier restoration [<xref rid="onco12378-bib-0010" ref-type="ref">10</xref>]. Indeed, corticosteroids could be reduced (in 56% of cases) or even discontinued (10%) in our patients with inoperable tumors. This steroid&#x02010;sparing effect is clearly favorable given the poor tolerance of elderly patients for steroids [<xref rid="onco12378-bib-0018" ref-type="ref">18</xref>].</p><p>Although the analysis included only 66 patients (5 patients were excluded because they did not take any dose of treatment), the precision obtained at the end of the trial of the estimation of the median survival was higher than expected (standard error of 5 weeks instead of 14 weeks). Additionally, the estimated OS median of 24 weeks that we found appears higher that the 12 weeks of OS that we found in a similar patient population treated with supportive care alone (personal data, unpublished). However, it is comparable to the 25 weeks that we reported in similar patients receiving TMZ alone [<xref rid="onco12378-bib-0009" ref-type="ref">9</xref>]. Whether this combination is superior to TMZ alone remains to be demonstrated by a randomized study.</p></sec><sec id="onco12378-sec-1117"><title>Figures and Tables</title><table-wrap id="onco12378-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1.</label><caption><title>Baseline patient characteristics</title></caption><graphic id="nlm-graphic-9" specific-use="sourcefile-name" xlink:href="onco12378-tbl-0003"><alt-text>image</alt-text><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></graphic><table-wrap-foot><fn id="onco12378-note-0002"><p>Abbreviations: Bev, bevacizumab; MMSE, mini&#x02010;mental state examination; TMZ, temozolomide.</p></fn></table-wrap-foot></table-wrap><table-wrap id="onco12378-tbl-0002" xml:lang="en" orientation="portrait" position="float"><label>Table 2.</label><caption><title>Number of patients with grade&#x02009;&#x02265;&#x02009;3 adverse events</title></caption><graphic id="nlm-graphic-11" specific-use="sourcefile-name" xlink:href="onco12378-tbl-0004"><alt-text>image</alt-text><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></graphic></table-wrap><table-wrap id="onco12378-tbl-0003" xml:lang="en" orientation="portrait" position="float"><label>Table 3.</label><caption><title>Variations in MMSE and HRQoL scores over time before progression</title></caption><graphic id="nlm-graphic-13" specific-use="sourcefile-name" xlink:href="onco12378-tbl-0005"><alt-text>image</alt-text><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></graphic><table-wrap-foot><fn id="onco12378-note-0003"><p>Abbreviations: HRQoL, health&#x02010;related quality of life; MMSE, mini&#x02010;mental state examination; QLQ&#x02010;BN20, quality of life questionnaire, brain cancer module; QLQ&#x02010;C30, quality of life core questionnaire.</p></fn></table-wrap-foot></table-wrap><boxed-text position="float" orientation="portrait"><p>See <ext-link ext-link-type="uri" xlink:href="http://www.TheOncologist.com">http://www.TheOncologist.com</ext-link> for supplemental material available online.</p></boxed-text></sec></body><back><ack id="onco12378-sec-0015"><title>Acknowledgments</title><p>We thank the patients and their families for their participation in this clinical trial, as well as the data managers, nurses, and physicians involved in the study for their support and care.</p></ack><fn-group><fn fn-type="other" id="onco12378-note-2201"><p><ext-link ext-link-type="uri" xlink:href="http://ClinicalTrials.gov">ClinicalTrials.gov</ext-link> Identifier: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT02898012">NCT02898012</ext-link></p><p><bold>Sponsor(s)</bold>: Institut National du Cancer (PHRC program); Roche; Assistance Publique &#x02013; H&#x000f4;pitaux de Paris</p><p><bold>Principal Investigator</bold>: Jean&#x02010;Yves Delattre</p><p><bold>IRB Approved</bold>: Yes</p></fn><fn id="onco12378-note-4392"><p><ext-link ext-link-type="uri" xlink:href="http://theoncologist.alphamedpress.org/cgi/collection/clinical-trial-results">Click here to access other published clinical trials</ext-link>.</p></fn></fn-group><sec id="onco12378-sec-0016" sec-type="disclosure"><title>Disclosures</title><p><bold>Olivier Chinot:</bold> Roche, IPSEN Celldex (C/A), Servier, Astra&#x02010;Zeneca (H). The other authors indicated no financial relationships.</p><p>(C/A) Consulting/advisory relationship; (RF) Research funding; (E) Employment; (ET) Expert testimony; (H) Honoraria received; (OI) Ownership interests; (IP) Intellectual property rights/inventor/patent holder; (SAB) Scientific advisory board</p></sec><ref-list content-type="cited-references"><title>References</title><ref id="onco12378-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="onco12378-cit-0001">
<string-name><surname>Dolecek</surname>
<given-names>TA</given-names></string-name>, 
<string-name><surname>Propp</surname>
<given-names>JM</given-names></string-name>, 
<string-name><surname>Stroup</surname>
<given-names>NE</given-names></string-name> et al. <article-title>CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2005&#x02013;2009</article-title>. <source xml:lang="en">Neuro Oncol</source>
<year>2012</year>;<volume>14</volume>(<issue>suppl 5</issue>):<fpage>v1</fpage>&#x02013;<lpage>v49</lpage>.
<pub-id pub-id-type="pmid">23095881</pub-id></mixed-citation></ref><ref id="onco12378-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="onco12378-cit-0002">
<string-name><surname>Fleury</surname>
<given-names>A</given-names></string-name>, 
<string-name><surname>Menegoz</surname>
<given-names>F</given-names></string-name>, 
<string-name><surname>Grosclaude</surname>
<given-names>P</given-names></string-name> et al. <article-title>Descriptive epidemiology of cerebral gliomas in France</article-title>. <source xml:lang="en">Cancer</source>
<year>1997</year>;<volume>79</volume>:<fpage>1195</fpage>&#x02013;<lpage>1202</lpage>.
<pub-id pub-id-type="pmid">9070498</pub-id></mixed-citation></ref><ref id="onco12378-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="onco12378-cit-0003">
<string-name><surname>Keime&#x02010;Guibert</surname>
<given-names>F</given-names></string-name>, 
<string-name><surname>Chinot</surname>
<given-names>O</given-names></string-name>, 
<string-name><surname>Taillandier</surname>
<given-names>L</given-names></string-name> et al. <article-title>Radiotherapy for glioblastoma in the elderly</article-title>. <source xml:lang="en">N Engl J Med</source>
<year>2007</year>;<volume>356</volume>:<fpage>1527</fpage>&#x02013;<lpage>1535</lpage>.
<pub-id pub-id-type="pmid">17429084</pub-id></mixed-citation></ref><ref id="onco12378-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="onco12378-cit-0004">
<string-name><surname>Malmstr&#x000f6;m</surname>
<given-names>A</given-names></string-name>, 
<string-name><surname>Gr&#x000f8;nberg</surname>
<given-names>BH</given-names></string-name>, 
<string-name><surname>Marosi</surname>
<given-names>C</given-names></string-name> et al. <article-title>Temozolomide versus standard 6&#x02010;week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: The Nordic randomised, phase 3 trial</article-title>. <source xml:lang="en">Lancet Oncol</source>
<year>2012</year>;<volume>13</volume>:<fpage>916</fpage>&#x02013;<lpage>926</lpage>.
<pub-id pub-id-type="pmid">22877848</pub-id></mixed-citation></ref><ref id="onco12378-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="onco12378-cit-0005">
<string-name><surname>Wick</surname>
<given-names>W</given-names></string-name>, 
<string-name><surname>Platten</surname>
<given-names>M</given-names></string-name>, 
<string-name><surname>Meisner</surname>
<given-names>C</given-names></string-name> et al. <article-title>Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: The NOA&#x02010;08 randomised, phase 3 trial</article-title>. <source xml:lang="en">Lancet Oncol</source>
<year>2012</year>;<volume>13</volume>:<fpage>707</fpage>&#x02013;<lpage>715</lpage>.
<pub-id pub-id-type="pmid">22578793</pub-id></mixed-citation></ref><ref id="onco12378-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="onco12378-cit-0006">
<string-name><surname>Perry</surname>
<given-names>JR</given-names></string-name>, 
<string-name><surname>Laperriere</surname>
<given-names>N</given-names></string-name>, 
<string-name><surname>O'Callaghan</surname>
<given-names>CJ</given-names></string-name> et al. <article-title>A phase III randomized controlled trial of short&#x02010;course radiotherapy with or without concomitant and adjuvant temozolomide in elderly patients with glioblastoma (CCTG CE.6, EORTC 26062&#x02010;22061, TROG 08.02, NCT00482677)</article-title>. <source xml:lang="en">J Clin Oncol</source>
<year>2016</year>;<volume>34</volume>(<issue>suppl 18</issue>):<fpage>LBA2A</fpage>.
</mixed-citation></ref><ref id="onco12378-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="onco12378-cit-0007">
<string-name><surname>Stupp</surname>
<given-names>R</given-names></string-name>, 
<string-name><surname>Mason</surname>
<given-names>WP</given-names></string-name>, 
<string-name>
<surname>van den Bent</surname>
<given-names>MJ</given-names></string-name> et al. <article-title>Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma</article-title>. <source xml:lang="en">N Engl J Med</source>
<year>2005</year>;<volume>352</volume>:<fpage>987</fpage>&#x02013;<lpage>996</lpage>.
<pub-id pub-id-type="pmid">15758009</pub-id></mixed-citation></ref><ref id="onco12378-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="onco12378-cit-0008">
<string-name><surname>Roa</surname>
<given-names>W</given-names></string-name>, 
<string-name><surname>Kepka</surname>
<given-names>L</given-names></string-name>, 
<string-name><surname>Kumar</surname>
<given-names>N</given-names></string-name> et al. <article-title>International Atomic Energy Agency randomized phase III study of radiation therapy in elderly and/or frail patients with newly diagnosed glioblastoma multiforme</article-title>. <source xml:lang="en">J Clin Oncol</source>
<year>2015</year>;<volume>33</volume>:<fpage>4145</fpage>&#x02013;<lpage>4150</lpage>.
<pub-id pub-id-type="pmid">26392096</pub-id></mixed-citation></ref><ref id="onco12378-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="onco12378-cit-0009">
<string-name><surname>G&#x000e1;llego P&#x000e9;rez&#x02010;Larraya</surname>
<given-names>J</given-names></string-name>, 
<string-name><surname>Ducray</surname>
<given-names>F</given-names></string-name>, 
<string-name><surname>Chinot</surname>
<given-names>O</given-names></string-name> et al. <article-title>Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: An ANOCEF phase II trial</article-title>. <source xml:lang="en">J Clin Oncol</source>
<year>2011</year>;<volume>29</volume>:<fpage>3050</fpage>&#x02013;<lpage>3055</lpage>.
<pub-id pub-id-type="pmid">21709196</pub-id></mixed-citation></ref><ref id="onco12378-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="onco12378-cit-0010">
<string-name><surname>Chinot</surname>
<given-names>OL</given-names></string-name>, 
<string-name><surname>Wick</surname>
<given-names>W</given-names></string-name>, 
<string-name><surname>Mason</surname>
<given-names>W</given-names></string-name> et al. <article-title>Bevacizumab plus radiotherapy&#x02010;temozolomide for newly diagnosed glioblastoma</article-title>. <source xml:lang="en">N Engl J Med</source>
<year>2014</year>;<volume>370</volume>:<fpage>709</fpage>&#x02013;<lpage>722</lpage>.
<pub-id pub-id-type="pmid">24552318</pub-id></mixed-citation></ref><ref id="onco12378-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="onco12378-cit-0011">
<string-name><surname>Gilbert</surname>
<given-names>MR</given-names></string-name>, 
<string-name><surname>Dignam</surname>
<given-names>JJ</given-names></string-name>, 
<string-name><surname>Armstrong</surname>
<given-names>TS</given-names></string-name> et al. <article-title>A randomized trial of bevacizumab for newly diagnosed glioblastoma</article-title>. <source xml:lang="en">N Engl J Med</source>
<year>2014</year>;<volume>370</volume>:<fpage>699</fpage>&#x02013;<lpage>708</lpage>.
<pub-id pub-id-type="pmid">24552317</pub-id></mixed-citation></ref><ref id="onco12378-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="onco12378-cit-0012">
<string-name><surname>Taal</surname>
<given-names>W</given-names></string-name>, 
<string-name><surname>Oosterkamp</surname>
<given-names>HM</given-names></string-name>, 
<string-name><surname>Walenkamp</surname>
<given-names>AM</given-names></string-name> et al. <article-title>Single&#x02010;agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): A randomised controlled phase 2 trial</article-title>. <source xml:lang="en">Lancet Oncol</source>
<year>2014</year>;<volume>15</volume>:<fpage>943</fpage>&#x02013;<lpage>953</lpage>.
<pub-id pub-id-type="pmid">25035291</pub-id></mixed-citation></ref><ref id="onco12378-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="onco12378-cit-0013">
<string-name><surname>Wick</surname>
<given-names>W</given-names></string-name>, 
<string-name><surname>Brandes</surname>
<given-names>AA</given-names></string-name>, 
<string-name><surname>Gorlia</surname>
<given-names>T</given-names></string-name> et al. <article-title>EORTC 26101 phase III trial exploring the combination of bevacizumab and lomustine in patients with first progression of a glioblastoma</article-title>. <source xml:lang="en">J Clin Oncol</source>
<year>2016</year>;<volume>34</volume>(<issue>suppl 15</issue>):<fpage>2001A</fpage>.
</mixed-citation></ref><ref id="onco12378-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="onco12378-cit-0014">
<string-name><surname>Lou</surname>
<given-names>E</given-names></string-name>, 
<string-name><surname>Peters</surname>
<given-names>KB</given-names></string-name>, 
<string-name><surname>Sumrall</surname>
<given-names>AL</given-names></string-name> et al. <article-title>Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma</article-title>. <source xml:lang="en">Cancer Med</source>
<year>2013</year>;<volume>2</volume>:<fpage>185</fpage>&#x02013;<lpage>195</lpage>.
<pub-id pub-id-type="pmid">23634286</pub-id></mixed-citation></ref><ref id="onco12378-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="onco12378-cit-0015">
<string-name><surname>Friedman</surname>
<given-names>HS</given-names></string-name>, 
<string-name><surname>Prados</surname>
<given-names>MD</given-names></string-name>, 
<string-name><surname>Wen</surname>
<given-names>PY.</given-names></string-name> et al. <article-title>Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma</article-title>. <source xml:lang="en">J Clin Oncol</source>
<year>2009</year>;<volume>27</volume>:<fpage>4733</fpage>&#x02013;<lpage>4740</lpage>.
<pub-id pub-id-type="pmid">19720927</pub-id></mixed-citation></ref><ref id="onco12378-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="onco12378-cit-0016">
<string-name><surname>Chauffert</surname>
<given-names>B</given-names></string-name>, 
<string-name><surname>Feuvret</surname>
<given-names>L</given-names></string-name>, 
<string-name><surname>Bonnetain</surname>
<given-names>F</given-names></string-name> et al. <article-title>Randomized phase II trial of irinotecan and bevacizumab as neo&#x02010;adjuvant and adjuvant to temozolomide&#x02010;based chemoradiation compared with temozolomide&#x02010;chemoradiation for unresectable glioblastoma: Final results of the TEMAVIR study from ANOCEF</article-title>. <source xml:lang="en">Ann Oncol</source>
<year>2014</year>;<volume>25</volume>:<fpage>1442</fpage>&#x02013;<lpage>1447</lpage>.
<pub-id pub-id-type="pmid">24723487</pub-id></mixed-citation></ref><ref id="onco12378-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="onco12378-cit-0017">
<string-name><surname>Scott</surname>
<given-names>JG</given-names></string-name>, 
<string-name><surname>Bauchet</surname>
<given-names>L</given-names></string-name>, 
<string-name><surname>Fraum</surname>
<given-names>TJ</given-names></string-name> et al. <article-title>Recursive partitioning analysis of prognostic factors for glioblastoma patients aged 70 years or older</article-title>. <source xml:lang="en">Cancer</source>
<year>2012</year>;<volume>118</volume>:<fpage>5595</fpage>&#x02013;<lpage>5600</lpage>.
<pub-id pub-id-type="pmid">22517216</pub-id></mixed-citation></ref><ref id="onco12378-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="onco12378-cit-0018">
<string-name><surname>Fardet</surname>
<given-names>L</given-names></string-name>, 
<string-name><surname>F&#x000e8;ve</surname>
<given-names>B.</given-names></string-name>
<article-title>Systemic glucocorticoid therapy: A review of its metabolic and cardiovascular adverse events</article-title>. <source xml:lang="en">Drugs</source>
<year>2014</year>;<volume>74</volume>:<fpage>1731</fpage>&#x02013;<lpage>1745</lpage>.
<pub-id pub-id-type="pmid">25204470</pub-id></mixed-citation></ref></ref-list></back></article>